Form D · Biotechnology
NeurAxon(USA), Inc.
Mississauga, A6 · CIK 0001486097
Offering snapshot reported May 1, 2012 · SEC filing
- Reported sold
- $782K Offering amount: $2.96M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 23, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 1, 2012 | Initial | $782,171 | No comparison | 4 | SEC filing |
| Mar 16, 2010 | Initial | $3,568,217 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-177521
Source: Form D, filed May 1, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John S. Andrews | Director, Executive |
| Lawrence E. Bloch | Director, Executive |
| Aaron Davidson | Director |
| Kenneth Galbraith | Director |
| Jonathan R. Goodman | Director |
| Tom Lategan | Executive |
| Shawn Maddaford | Executive |
| Robert A. Medve | Executive |
| Deepa Pakianathan | Director |
| Suman Rakhit | Executive |
| Andrew Sandham | Director |
| Samuel P. Wertheimer | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
2395 Speakman Drive Suite 1001
Mississauga, A6, L5K 1B3
Mississauga, A6, L5K 1B3